JHP Pharmaceuticals added a second product to an established multi-year contract with an undisclosed pharmaceutical company. JHP will be responsible for manufacturing and supply of an injectable anesthetic agent.
Stuart Hinchen president and chief executive officer of JHP, commented, “We are very pleased that JHP was chosen again by this well-established customer, as it speaks to their satisfaction with our work. We recently successfully completed an FDA (CBER) Pre-Approval Inspection in support of a biologic product launch for another long-term contract customer. JHP’s approach in meeting contract customer needs in a timely fashion creates an environment where customers are confident bringing additional manufacturing needs to us. Customers also rely on our extensive experience working with products throughout their life cycle which results in continuity of supply and program efficiencies.”